Anthracycline‑induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review)
- Authors:
- Fengfeng Cai
- Manuel Antonio Falar Luis
- Xiaoyan Lin
- Minghong Wang
- Lu Cai
- Chunmei Cen
- Ewelina Biskup
-
Affiliations: Department of Breast Surgery, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of General Practice, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China - Published online on: May 8, 2019 https://doi.org/10.3892/mco.2019.1854
- Pages: 15-23
-
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S and Noonan DM: Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 102:14–25. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
SEER Cancer Stat Facts: Female Breast Cancer. National Cancer Institute; Bethesda, MD: 2016, http://seer.cancer.gov/statfacts/html/breast.htmlApril. 2019 | |
|
Canadian Cancer Society's Advisory Committee on Cancer Statistics: Canadian cancer statistics 2016. Canadian Cancer Society. (Toronto, ON). 2016. | |
|
Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol Sci. 12:4465–4487. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarez RH: Present and future evolution of advanced breast cancer therapy. Breast Cancer Res. 12 (Suppl 2):S12010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF and Yeh ET: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mitry MA and Edwards JG: Doxorubicin induced heart failure: Phenotype and molecular mechanisms. Int J Cardiol Heart Vasc. 10:17–24. 2016.PubMed/NCBI | |
|
Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, et al: From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview. Antioxid Redox Signal. May 15–2017.(Epub ahead of print). PubMed/NCBI | |
|
Kaiserová H, Simůnek T, van der Vijgh WJ, Bast A and Kvasnicková E: Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta. 1772:1065–1074. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA and Redmond MD: Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res. 13:1945–1952. 1993.PubMed/NCBI | |
|
Mordente A, Meucci E, Silvestrini A, Martorana GE and Giardina B: New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 16:1656–1672. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sanguinetti MC and Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature. 440:463–469. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and clinical significance. Physiol Rev. 92:1393–1478. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jehle J, Schweizer PA, Katus HA and Thomas D: Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2:e1932011. View Article : Google Scholar : PubMed/NCBI | |
|
Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED and Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:795–803. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Jaworski C, Mariani JA, Wheeler G and Kaye DM: Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 61:2319–2328. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jain D, Russell RR, Schwartz RG, Panjrath GS and Aronow W: Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 19:362017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G and Liu S: Research progress in cardiotoxicity of antitumor chemotherapy drugs. J Oncol. 21:1010–1014. 2015. | |
|
Manrique CR, Park M, Tiwari N, Plana JC and Garcia MJ: Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol. 11:11795468176979832017. View Article : Google Scholar : PubMed/NCBI | |
|
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91:710–717. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Ryberg M, Nielsen D, Cortese G, Nielsen G and Andersen PK: New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 100:1058–1067. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 97:2869–2879. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tromp J, Steggink LC, Van Veldhuisen DJ, Gietema JA and van der Meer P: Cardio-oncology: Progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther. 101:481–490. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 63:37–45. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 383:2127–2135. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, de Vathaire F, Sidi D and Hartmann O: Cardiac abnormalities 15 years and more after Adriamycin therapy in 229 childhood survivors of a solid tumors at the Institute Gustave Roussy. Brit J Cancer. 91:37–44. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitz KH, Prosnitz RG, Schwartz AL and Carver JR: Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 118 (Suppl 8):S2270–S2276. 2012. View Article : Google Scholar | |
|
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al: Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 28:1–39.e14. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, Blaise AM, Elaerts J and Nazeyrollas P: Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 7:141–146. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jurcut R, Wildiers H, Ganame J, D'hooge J, De Backer J, Denys H, Paridaens R, Rademakers F and Voigt JU: Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr. 21:1283–1289. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mitani I, Jain D, Joska TM, Burtness B and Zaret BL: Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angio-cardiography in the current era. J Nucl Cardiol. 10:132–139. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, Atkinson P, Deman P and Wackers FJ: Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol. 77:843–850. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA and Lima JA: LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging. 5:837–848. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ng R, Better N and Green MD: Anticancer agents and cardiotoxicity. Semin Oncol. 33:2–14. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM and Yellon DM: Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX and Ferrans VJ: Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 17:2237–2243. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB and Ottlinger ME: Predictive value of cardiac troponin T in pedriatic patirnts at risk for myocardial injury. Circulation. 96:2641–2648. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Porcel JM: Utilization of B-type natriuretic peptide and NT-proBNP in the diagnosis of pleural effusions due to heart failure. Curr Opin Pulm Med. 17:215–219. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Zheng L, Zheng J, et al: Significance of N-terminal pro-brain natriuretic peptide in early monitoring of anthracycline chemotherapy in elderly patients with breast cancer. Chin J Gerontol. 6:2931–2933. 2014. | |
|
Angelis AD, Cappetta D, Berrino L and Urbanek K: Doxorubicin cardiotoxicity: Multiple targets and translational perspectives. IntechOpen. https://www.intechopen.com/books/cardiotoxicity/doxorubicin-cardiotoxicity-multiple-targets-and-translational-perspectivesNovember 14–2008 | |
|
De Angelis A, Urbanek K, Cappetta D, Piegari E, Pia Ciuffreda L, Rivellino A, Russo R, Esposito G, Rossi F and Berrino L: Doxorubicin cardiotoxicity and target cells: A broader perspective. Cardiooncology. 2:22016. | |
|
van Dalen EC, van der Pal HJ, Caron HN and Kremer LC: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. CD0050082009.PubMed/NCBI | |
|
Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr and Billingham ME: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med. 99:745–749. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Koene RJ, Prizment AE, Blaes A and Konety SH: Shared risk factors in cardiovascular disease and cancer. Circulation. 133:1104–1114. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L and Winer E; TLC D-99 Study Group, : Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastastic breast carcinoma. Cancer. 94:25–36. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Van Dalen EC, Caron HN, Dickinson HO and Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. CD0039172008.PubMed/NCBI | |
|
Che FF, Liu Y and Xu CG: Study on the effect and mechanism of dextromethionine on cardiotoxicity induced by doxorubicin. J Sichuan Univ. 41:24–28. 2010. | |
|
Gao X, Han Z and Du X: Observation of the effects of dextromethine on cardiotoxicity induced by epirubicin. Chin J Cancer Prev Treat. 17:296–298. 2010. | |
|
Professional Committee of Breast Cancer of China Anti-Cancer Association, . Basic principles of chemotherapy for recurrent and metastatic breast cancer. Chin J Med. 9:73–75. 2011. | |
|
Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S and Maggi CA: Cardioprotection effects of zofenopril, a new angiotension-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 414:71–78. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sacco G, Mario B, Lopez G, Evangelista S, Manzini S and Maggi CA: ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vascul Pharmacol. 50:166–170. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R and Ergin A: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 48:2258–2262. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Elbaky NAA, El-Orabi NF, Fadda LM, Abd-Elkader OH and Ali HM: Role of N-acetylcysteine and coenzyme Q10 in the amelioration of myocardial energy expenditure and oxidative stress, induced by carbon tetrachloride intoxication in rats. Dose-Response. 16:15593258187901582018. View Article : Google Scholar : PubMed/NCBI | |
|
Baker WL, Anglade MW, Baker EL, White CM, Kluger J and Coleman CI: Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: A meta-analysis. Eur J Cardiothorac Surg. 35:521–527. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A, Kaur H, Devi P and Mohan V: Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension, and meniere-like syndrome. Pharmacol Ther. 124:259–268. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
van Acker FA, Boven E, Kramer K, Haenen GR, Bast A and van der Vijgh WJ: Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res. 7:1378–1384. 2001.PubMed/NCBI | |
|
Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al: Cardiovascular disease and breast cancer: Where these entities intersect: A scientific statement from the American heart association. Circulation. 137:e30–e66. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M and Jones LW: Cancer therapy-induced cardiac toxicity in early breast cancer: Addressing the unresolved issues. Circulation. 126:2749–2763. 2012. View Article : Google Scholar : PubMed/NCBI |
